ArticleInternational endodontic journal2026
Dentine Regeneration With Calcium Strontium Silicate: In Vitro Odontogenic Differentiation, Antimicrobial Activity, Immunomodulation and In Vivo Pulpotomy in Rat Molars.
Article in International endodontic journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimThis study examined the in vitro and in vivo performance of calcium strontium silicate (CSR) as a novel biomaterial for vital pulp therapy (VPT), assessing its odontogenic differentiation, antibacterial activity, immunomodulation, inflammatory response and dentine regeneration potential compared to calcium silicate (CS) and Mineral Trioxide Aggregate (MTA). METHODOLOGY: CSR was synthesized via the sol-gel process. For the in vitro study, human dental pulp stem cells (HDPSCs) were assessed for viability, live/dead staining, trans-well migration assays and odontogenic gene expression (ALP, DSPP, DMP-1, RUNX2) using CCK-8, and RT-qPCR. Antibacterial activity against Streptococcus mutans and Lactobacillus acidophilus was assessed via colony- forming unit (CFU) counts. Immunomodulation was evaluated by RT-qPCR for inflammatory cytokines (IL-1β, TNF-α, IL-10). In the in vivo study, inflammatory responses were evaluated in Sprague-Dawley rats subjected to subcutaneous implantation for 7, 14 and 60 days, and pulpotomy procedures were performed on rat maxillary first molars and assessed after 30 and 60 days. The outcomes were analysed using micro-CT imaging and H&E staining. Statistical analyses included one-way ANOVA and non-parametric tests (p < 0.05).
resultsCSR significantly enhanced HDPSCs viability, migration and odontogenic gene expression compared to CS and MTA (p < 0.05). It exhibited superior antibacterial activity, with the lowest CFU counts (p < 0.05). CSR upregulated anti-inflammatory cytokine IL-10 and reduced pro-inflammatory cytokines. In vivo, CSR showed milder inflammation than CS and MTA at 7, 14 and 60 days (p < 0.05) and formed consistent calcified bridges in pulpotomy, with no pulp necrosis.
conclusionsCSR demonstrated superior biocompatibility, regenerative potential, and antibacterial properties making it a promising alternative to MTA for VPT, enhancing clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.